Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study

Objective To assess the association between use of sodium-glucose co-transporter 2 (SGLT2) inhibitors and risk of serious renal events in data from routine clinical practice. Design Cohort study using an active comparator, new user design and nationwide register data. Setting Sweden, Denmark, and Norway, 2013-18. Participants Cohort of 29 887 new users of SGLT2 inhibitors (follow-up time: dapagliflozin 66.1%; empagliflozin 32.6%; canagliflozin...